$WUXI BIO (02269.HK)$ Haitong International believes that th...
$WUXI BIO(02269.HK$
Haitong International believes that the U.S. Biomanufacturing Act will have limited impact on WuXi Biologics in the short and medium term. The bank said that WuXi Biologics will maintain rapid growth in revenue and profits in 2022-2023. Revenue growth is expected to be 47% and 37%, respectively, and profit growth is expected to be 47% and 38%, respectively. The company has advantages in emerging technology fields including double antibody and ADC, and the number and proportion of projects have increased. The company's Wuxi plant has been substantially unaffected by UVL.
Haitong International believes that the U.S. Biomanufacturing Act will have limited impact on WuXi Biologics in the short and medium term. The bank said that WuXi Biologics will maintain rapid growth in revenue and profits in 2022-2023. Revenue growth is expected to be 47% and 37%, respectively, and profit growth is expected to be 47% and 38%, respectively. The company has advantages in emerging technology fields including double antibody and ADC, and the number and proportion of projects have increased. The company's Wuxi plant has been substantially unaffected by UVL.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Moo Contributor
Follow me to get useful analysis, learn TA and make profitable trades.
Maximise profit 利润最大化
6532Followers
57Following
23KVisitors
Follow